| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Common Stock | Options Exercise | $1,691,221 | +19,417 | +33% | $87.10 | 78,557 | 02 Feb 2024 | Direct | |
| transaction | MRK | Common Stock | Sale | $6,284,779 | -49,499 | -63% | $126.97 | 29,058 | 02 Feb 2024 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Stock Option (Right to Buy) | Options Exercise | $0 | -19,417 | -33% | $0.000000 | 38,835 | 02 Feb 2024 | Common Stock | 19,417 | $87.10 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.8650 to $127.3000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F2 | Holdings include shares acquired in dividend reinvestment transactions. |
| F3 | The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |